Navigation Links
DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
Date:2/8/2011

development of state-of-the-art biodegradable, controlled-release injectable therapeutics.  The SABER technology is the basis of POSIDUR, which is in Phase III clinical trials in the U.S. and Phase II clinical trials in the E.U.  In addition, DURECT has a number of feasibility projects underway that utilize the SABER system for the delivery of various proteins and peptides for periods of up to one month from a single injection.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

About CreoSalus

CreoSalus is a privately held Louisville, Kentucky based life-sciences company specializing in the development and manufacturing of finished drugs, human medical devices, and fine chemicals.  The Company's three peptide-based businesses are Advanced ChemTech (fine chemicals), Occam Design (human medical devices), and Thorn BioScience (finished drugs).  Thorn BioScience's products include SucroMate™ Porcine (under development) and FDA approved Sucr
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. DURECT to Present at the BIO CEO & Investor Conference
2. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
3. DURECT Corporation Announces Third Quarter 2010 Financial Results
4. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
5. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
6. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
7. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
8. DURECT to Present at the Jefferies Global Life Sciences Conference
9. DURECT to Present at the Rodman & Renshaw Global Healthcare Conference
10. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
11. DURECT to Present at the Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... BEIJING , May 24, 2013  Sinovac ... leading provider of biopharmaceutical products in ... main operating subsidiary company of Sinovac, obtained the ... (GMP Certificate) from the China State and Food ... district bulk production plants, and its Changping filing ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... MERCER ISLAND, Wash., Dec. 22, 2010 Renal Advantage and ... the third largest provider of dialysis services in the U.S., ... – terms of which were not disclosed – was completed ... serving more than 19,000 patients in 260 locations in 32 ...
... AstraZeneca (NYSE: AZN ... will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric ... dyslipidemia. This means the co-development and license agreement with Abbott ... Complete Response Letter (CRL) for the CERTRIAD New Drug Application ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:5/25/2013)... Pompton Plains, NJ (PRWEB) May 25, 2013 ... Apple’s iPhone. The universal app version of Word Hunt ... Universal app versions of Concentration, Edge Match, Flash 2, Sudoku ... , The brain games’ gameplay and revolutionary lifetime brain ... and 4 inch displays. , “100 years of brain fitness ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the Cell Therapy ... 28.7% to $1.0 billion in the five years to 2013, ... no new cell therapy products were introduced, according to IBISWorld ... period. In the years since, however, the Food and Drug ... to the industry's fast growth during the five years to ...
(Date:5/25/2013)... For college students, few events ... they are turning to prescription stimulants like Adderall ... more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . ... that students who pick up Adderall, “just to ... developing a physical and psychological dependency. While initially ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of ... of life". While a medical science, its scope enters into ... Its fundamental philosophy is that disease is the end result ... that in order to re-establish optimal health, we must discover ... a life style which brings us back into harmony. , ...
(Date:5/25/2013)... Arizona (PRWEB) May 25, 2013 The current ... Center, their parents, and the B2B staff all came together ... everyone enjoyed an array of Indian Cuisine, the residents got ... company, for helping them on their road to recovery, and ... the Drug and Alcohol center in 2010 after realizing the ...
Breaking Medicine News(10 mins):Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2
... Minneapolis for a one-day summit on Jan. 20, to ... (ICD) leads, which recently underwent a Class I FDA ... Mayo Clinic have organized the summit to develop a ... leads. Approximately 80,000 active patients have Riata or ...
... instance when the smaller sibling gets to call the shots ... has long been known to be a checkpoint in cell ... until their DNA has been fully replicated or repaired. Now ... of Technology have discovered a shorter form they,ve dubbed Chk1-S ...
... HealthDay Reporter , MONDAY, Jan. 2 (HealthDay News) ... at relieving neck pain in the long term than ... spinal manipulation therapy for neck pain also reported greater ... "We found that there are some viable ...
... Pirfenidone inhibits the development of inflammation and scarring (fibrosis) ... treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) ... assessment in accordance with the Act on the Reform ... Institute for Quality and Efficiency in Health Care (IQWiG) ...
... (Boston) - The first-ever published whole-genome sequences of not just ... that both unusual and common genetic phenomena contribute to the ... the study -- led by researchers from the Boston University ... -- will be available to researchers around the world at ...
... State University researchers one working at a medieval burial ... East Lansing have shown how modern science can unlock ... first to confirm the existence of brucellosis, an infectious disease ... findings, which appear in the American Journal of Physical ...
Cached Medicine News:Health News:Summit seeks to inform electrophysiologists on Riata ICD recall 2Health News:Smaller sibling protein calls the shots in cell division 2Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 2Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 3Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 4Health News:Pirfenidone: Extent of added benefit assessed 2Health News:Pirfenidone: Extent of added benefit assessed 3Health News:Genetic predisposition to disease common in 2 supercentenarians: New study 2Health News:Scientists crack medieval bone code 2
... BioControl multichannel has the ... the single channel model.The ... all seven multichannel and ... cone modules. Both pipettes ...
... in a wide variety of applications. • Whole ... can be freely rotated against the handle to ... an optimum angle towards the microtiter plate. • ... of most common pipette tips, and provides a ...
... value!, Comfortable feel and less hand ... Finer control while pipetting with smooth, light ... with long, lever tip ejector , Completely ... the need for recalibration , Easy-to-read precision ...
... Designed with 96-well plates in ... useful for molecular biology applications: PCR* ... 96-well plates, etc. Used with Diamond ... system, this product will maximize performance ...
Medicine Products: